The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.

Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of developing the disease, the study found

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer's disease, a new study published Thursday finds.

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.

Semaglutide might help ward off Alzheimer’s disease, a new study says. Type 2 diabetics taking the drug had a lower risk of Alzheimer’s compared to patients on other diabetes

In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.